Danielle Townsley
Seminars
Tuesday 6th October 2026
Do We Need Enrichment? Clinical & Translational Learnings from Amgen T-Cell Engagers
3:20 pm
- Tarlatamab and xaluritamig (STEAP1) demonstrate clinical activity across a broad range of target expression levels, with no clear IHC cut-off for response
- Beyond tumor antigen expression, what alternative determinants may drive response or resistance?
- To what extent might factors such as the tumor microenvironment, immune cell fitness, or other non-target antigen features influence clinical benefit?
